Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hengrui Yuanzheng (Shanghai) Biotechnology

Request full access

Developing precision medicines and immunotherapies for solid tumors

ChinaFounded 2015Biotech & Life Sciences

About Hengrui Yuanzheng (Shanghai) Biotechnology

Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. is a biopharmaceutical company founded in 2015, specializing in the development of precision medicines and immunotherapy products for solid tumors. The company was established as a joint venture between Jiangsu Hengrui Pharmaceuticals Group and Shenzhen Yuanzheng Cell. The company is headquartered in Shanghai, with wholly-owned subsidiaries and cell therapy research centers in Shenzhen and Guangzhou.

The company's core technology is the Multiple Antigen Specific Cell Therapy (MASCT), described as a fourth-generation tumor autologous immune cell therapy technique. Their primary product, the multi-antigen autologous immune cell injection (MASCT-I), has received approval for clinical trials from the National Medical Products Administration of China and is currently in Phase II trials for treating advanced soft tissue sarcoma. Hengrui Yuanzheng's product pipeline also includes TCR-T immune cell products and TCR bispecific antibody products. The company focuses on developing treatments for a variety of cancers, including melanoma, non-small cell lung cancer, breast cancer, colorectal cancer, and soft tissue sarcomas.

Hengrui Yuanzheng has secured multiple rounds of funding, including a Series A, and subsequent B, C, and C++ rounds with investments from firms like Green Pine Capital Partners, Sincere VC, and CICC Capital. The company has a team of nearly 100 professionals dedicated to the research, development, and production of its innovative drugs. The chairman of the parent company, Hengrui Pharma, is Sun Piaoyang. The legal representative of Hengrui Yuanzheng is Li Kejian.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
23.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Jan 2024 $14M $138M China Science and Technology Innovation · Goldport Capital ↗
SERIES C✓Equity / VC May 2023 $28M $110M China Science and Technology Innovation · Hengrui Pharma · Goldport Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Hengrui Yuanzheng (Shanghai) Biotechnology website traffic

Latest recorded traffic for Hengrui Yuanzheng (Shanghai) Biotechnology is 700 monthly website visits, up 1650% over the last three months. Hengrui Yuanzheng (Shanghai) Biotechnology's team grew 0% over the past year.

Latest monthly visits700 3-month web change+1650% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hengrui Yuanzheng (Shanghai) Biotechnology in its local ecosystem

Live from Dealroom

The Hengrui Yuanzheng (Shanghai) Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • China Science and Technology Innovation
  • Hengrui Pharma
  • Goldport Capital

Other known investors1 additional known investor

  • Shanghai Jiao Tong University
Employees 10 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hengrui Yuanzheng (Shanghai) Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hengrui Yuanzheng (Shanghai) Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.